非洲疾病控制中心计划在刚果民主共和国东部使用现有的寨卡埃博拉病毒疫苗来应对传播速度异常快的邦迪布焦病毒株疫情[1]。截至周二，该疫情已确认病例3973例，死亡1801例[1]。非洲疾病控制中心主任让·卡塞亚表示："我们看到接种疫苗的人中零死亡事件"[1]。世卫组织和非洲疾病控制中心将启动研究以检查病毒是否存在变异或其他异常[1]。
当前疫情的传播特征显著异常。邦迪布焦病毒株导致的死亡速度是2018至2020年寨卡病毒株疫情的6倍[1]。疫情已扩散到51个卫生区，而5月疫情宣布时仅涉及9个卫生区[1]。刚果民主共和国内接触者的感染率也大幅上升，每10名接触者中有1例确诊病例，相比之下2018至2020年疫情为每57名接触者1例[1]。疫情于5月中旬宣布以来，已成为历史第二大埃博拉疫情[1]。乌干达使用瑞德西韦治疗的20例病例中仅有2例死亡[1]。
The Africa Centers for Disease Control and Prevention has announced plans to utilize existing Zaire Ebola vaccine supplies to combat a rapidly spreading Bundibugyo Ebola outbreak in eastern Democratic Republic of Congo [1]. The decision comes as the current epidemic demonstrates transmission rates six to eight times faster than historical records, with confirmed cases reaching 3,973 and deaths totaling 1,801 as of Tuesday [1].
The Bundibugyo strain is proving significantly more lethal than previous Ebola outbreaks. The virus has caused deaths at a rate six times higher than the 2018-2020 Zaire strain epidemic, and contact tracing data reveals a stark difference in transmission efficiency: one confirmed case now emerges per ten contacts compared to one per 57 during the earlier crisis [1]. The outbreak, which was declared in mid-May, has expanded dramatically across the affected region, spreading to 51 health zones from just nine at the outbreak's start [1].
The World Health Organization and Africa CDC have launched investigations to determine whether the virus has undergone mutations or exhibits other abnormalities [1]. Notably, Africa CDC Director Jean Kaseya reported that vaccination efforts have yielded encouraging results, stating "we have seen zero deaths among people who have been vaccinated" [1]. Uganda's experience with the antiviral drug remdesivir has also shown promise, with only two deaths recorded among 20 treated cases [1].